RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
Major Pharamceuticals
Drug class
Osteoporosis Agents
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk. Read more about Osteoporosis Agents
114 drugs in this class 61 manufacturers
Drugs in Osteoporosis Agents
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
GSK Consumer Healthcare
RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
NORTHSTAR RX LL
RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
APHENA PHARMA S
TERIPARATIDE
OSTEOPOROSIS AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+2
ALVOGEN INC
RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
AVPAK
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
A-S MEDICATION
RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
A-S MEDICATION
CALCITONIN-SALMON (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
DR.REDDY'S LAB
Filter & compare in the drug finder →
Opens the drug finder with Osteoporosis Agents preselected. Add indication or manufacturer filters there.
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk.
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation.
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss.
-
fda.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.